In a study, patients with neuropathic pruritus showed significantly higher rates of anxiety, depression, sleep disorders, type 2 diabetes, obesity, and falls than healthy individuals, in a study that ...

Cara Therapeutics, a Stamford-based biopharmaceutical company, saw its financial struggles continue in the third quarter despite its major restructuring efforts. In a quarterly report filed with the U ...

Cara Therapeutics said its Notalgia Paresthetica drug failed in clinical trials. The company is looking at strategic alternatives. Get daily-updated rankings across momentum, growth, value, trends, ...

On Thursday, Cara Therapeutics Inc. (NASDAQ:CARA) stock experienced a significant shift in market expectations after Stifel downgraded the stock from Buy to Hold. The investment firm also adjusted the ...

- Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo - - Company will discontinue clinical program in NP and explore strategic alternatives - STAMFORD, Conn., June ...

June 12 (Reuters) - Cara Therapeutics (CARA.O), opens new tab said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its oral drug did ...

– Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage ...

STAMFORD, Conn. - Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on pruritus treatments, has announced the discontinuation of its clinical program for notalgia paresthetica ...